The DOI matches its Crossref record; 346 of the 346 references it cites were found in a registry or an index.
An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
Open accessAbstract
Sodium-glucose co-transporter 2 (SGLT2) inhibitors block glucose reabsorption in the renal proximal tubule, an insulin-independent mechanism that plays a critical role in glycemic regulation in diabetes. In addition to their glucose-lowering effects, SGLT2 inhibitors prevent both renal damage and the onset of chronic kidney disease and cardiovascular events, in particular heart failure with both reduced and preserved ejection fraction. These unexpected benefits prompted changes in treatment guidelines and scientific interest in the underlying mechanisms. Aside from the target effects of SGLT2 inhibition, a wide spectrum of beneficial actions is described for the kidney and the heart, even though the cardiac tissue does not express SGLT2 channels. Correction of cardiorenal risk factors, metabolic adjustments ameliorating myocardial substrate utilization, and optimization of ventricular loading conditions through effects on diuresis, natriuresis, and vascular function appear to be the main underlying mechanisms for the observed cardiorenal protection. Additional clinical advantages associated with using SGLT2 inhibitors are antifibrotic effects due to correction of inflammation and oxidative stress, modulation of mitochondrial function, and autophagy. Much research is required to understand the numerous and complex pathways involved in SGLT2 inhibition. This review summarizes the current known mechanisms of SGLT2-mediated cardiorenal protection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–346 of 346
Cefalu, W. T., Stenlöf, K., Leiter, L. A., Wilding, J. P. H., Blonde, L., Polidori, D., Xie, J., Sullivan, D., Usiskin, K., Canovatchel, W. J., et al. (2015) · Diabetologia · doi:10.1007/s00125-015-3547-2 · Cited by 141
Lee, N., Heo, Y. J., Choi, S.-E., Jeon, J. Y., Han, S. J., Kim, D. J., Kang, Y., Lee, K. W., & Kim, H. J. (2021) · Journal of Immunology Research · doi:10.1155/2021/9944880 · Cited by 139
Durante, W., Behnammanesh, G., & Peyton, K. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168786 · Cited by 139
Oshima, M., Neuen, B. L., Jardine, M. J., Bakris, G., Edwards, R., Levin, A., Mahaffey, K. W., Neal, B., Pollock, C., Rosenthal, N., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30300-4 · Cited by 135
Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor
Lapuerta, P., Zambrowicz, B., Strumph, P., & Sands, A. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114563304 · Cited by 134
SGLT2 Inhibitors Play a Salutary Role in Heart Failure via Modulation of the Mitochondrial Function
Maejima, Y. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2019.00186 · Cited by 134
Zhou, Z., Jardine, M., Li, Q., Neuen, B. L., Cannon, C. P., de Zeeuw, D., Edwards, R., Levin, A., Mahaffey, K. W., Perkovic, V., et al. (2021) · Stroke · doi:10.1161/strokeaha.120.031623 · Cited by 134
Sasso, F. C., Pafundi, P. C., Simeon, V., Nicola, L. D., Chiodini, P., Galiero, R., Rinaldi, L., Nevola, R., Salvatore, T., Sardu, C., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01343-1 · Cited by 134
Self-citationJensen, J., Omar, M., Kistorp, C., Tuxen, C., Gustafsson, I., Køber, L., Gustafsson, F., Faber, J. O., Malik, M. E., Fosbøl, E. L., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30382-x · Cited by 133
Tahara, A., Kurosaki, E., Yokono, M., Yamajuku, D., Kihara, R., Hayashizaki, Y., Takasu, T., Imamura, M., Li, Q., Tomiyama, H., et al. (2014) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12223 · Cited by 132
Bosch, A., Ott, C., Jung, S., Striepe, K., Karg, M. V., Kannenkeril, D., Dienemann, T., & Schmieder, R. E. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0839-8 · Cited by 132
Packer, M. (2020) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020010010 · Cited by 132
Xu, J., Kitada, M., Ogura, Y., Liu, H., & Koya, D. (2021) · Cells · doi:10.3390/cells10061457 · Cited by 131
Georgianos, P. I., & Agarwal, R. (2019) · Diabetes Care · doi:10.2337/dc18-2207 · Cited by 130
Ipragliflozin improves mitochondrial abnormalities in renal tubules induced by a high‐fat diet
Takagi, S., Li, J., Takagaki, Y., Kitada, M., Nitta, K., Takasu, T., Kanasaki, K., & Koya, D. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12802 · Cited by 129
Xu, L., Nagata, N., Chen, G., Nagashimada, M., Zhuge, F., Ni, Y., Sakai, Y., Kaneko, S., & Ota, T. (2019) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000783 · Cited by 128
Prattichizzo, F., Nigris, V. D., Micheloni, S., Sala, L. L., & Ceriello, A. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13488 · Cited by 124
Salim, H. M., Fukuda, D., Yagi, S., Soeki, T., Shimabukuro, M., & Sata, M. (2016) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2016.00043 · Cited by 123
Birnbaum, Y., Bajaj, M., Yang, H., & Ye, Y. (2018) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-018-6778-x · Cited by 123
Mammalian ion‐coupled solute transporters.
Hediger, M. A., Kanai, Y., You, G., & Nußberger, S. (1995) · The Journal of Physiology · doi:10.1113/jphysiol.1995.sp020559 · Cited by 121
Ishibashi, Y., Matsui, T., & Yamagishi, S. (2015) · Hormone and Metabolic Research · doi:10.1055/s-0035-1555791 · Cited by 119
Korbut, A. I., Taskaeva, I. S., Bgatova, N. P., Muraleva, N. A., Орлов, Н. Б., Dashkin, M. V., Khotskina, А. S., Zavyalov, E. L., Konenkov, V. I., Klein, T., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082987 · Cited by 119
Hasan, R., Lasker, S., Hasan, A., Zerin, F., Zamila, M., Chowdhury, F. I., Nayan, S. I., Rahman, M. M., Khan, F., Subhan, N., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-71449-1 · Cited by 119
Empagliflozin Inhibits Na+/H+ Exchanger Activity in Human Atrial Cardiomyocytes
Trum, M., Riechel, J., Lebek, S., Pabel, S., Sossalla, S. T., Hirt, S. W., Arzt, M. E., Maier, L. S., & Wagner, S. (2020) · ESC Heart Failure · doi:10.1002/ehf2.13024 · Cited by 119
Cardioprotective Potential of an SGLT2 Inhibitor Against Doxorubicin-Induced Heart Failure
Oh, C., Cho, S., Jang, J., Kim, H., Chun, S., Choi, M., Park, S., & Ko, Y. (2019) · Korean Circulation Journal · doi:10.4070/kcj.2019.0180 · Cited by 116
Majewski, C., & Bakris, G. L. (2015) · Diabetes Care · doi:10.2337/dc14-1596 · Cited by 115
Jaikumkao, K., Pongchaidecha, A., Chueakula, N., Thongnak, L., Wanchai, K., Chatsudthipong, V., Chattipakorn, N., & Lungkaphin, A. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13441 · Cited by 113
Das, N. A., Carpenter, A. J., Belenchia, A. M., Aroor, A. R., Noda, M., Siebenlist, U. K., Chandrasekar, B., & DeMarco, V. G. (2019) · Cellular Signalling · doi:10.1016/j.cellsig.2019.109506 · Cited by 113
Takiyama, Y., & Haneda, M. (2014) · BioMed Research International · doi:10.1155/2014/837421 · Cited by 112
Hasan, R., Lasker, S., Hasan, A., Zerin, F., Zamila, M., Parvez, F., Rahman, M. M., Khan, F., Subhan, N., & Alam, M. A. (2020) · Scientific Reports · doi:10.1038/s41598-020-71599-2 · Cited by 111
SGLT2-inhibitors; more than just glycosuria and diuresis
Fathi, A., Vickneson, K., & Singh, J. S. (2021) · Heart Failure Reviews · doi:10.1007/s10741-020-10038-w · Cited by 109
Packer, M. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13229 · Cited by 108
CaMKII as a target for arrhythmia suppression
Mustroph, J., Neef, S., & Maier, L. S. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.10.006 · Cited by 107
MAP17 Is a Necessary Activator of Renal Na+/Glucose Cotransporter SGLT2
Coady, M. J., El Tarazi, A., Santer, R., Bissonnette, P., Sasseville, L. J., Calado, J., Lussier, Y., Dumayne, C., Bichet, D. G., & Lapointe, J.-Y. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015111282 · Cited by 106 · cited 1×
“The NHE3 exchangers colocalize with SGLT2 symporters, and their activities are linked via the accessory membrane-associated protein 17 [58].”
BackgroundEmpagliflozin prevents cardiomyopathy via sGC-cGMP-PKG pathway in type 2 diabetes mice
Xue, M., Li, T., Wang, Y., Chang, Y., Cheng, Y., Lu, Y., Liu, X., Xu, L., Li, X., Yu, X., et al. (2019) · Clinical Science · doi:10.1042/cs20190585 · Cited by 106
Lunder, M., Janić, M., Japelj, M., Juretič, A., Janež, A., & Šabović, M. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0797-6 · Cited by 105
SGLT2 Inhibitors: Nephroprotective Efficacy and Side Effects
Garofalo, C., Borrelli, S., Liberti, M., Andreucci, M., Conte, G., Minutolo, R., Provenzano, M., & Nicola, L. D. (2019) · Medicina · doi:10.3390/medicina55060268 · Cited by 105
Packer, M. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1732 · Cited by 105
Chen, H., Tran, D., Yang, H., Nylander, S., Birnbaum, Y., & Ye, Y. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-06978-y · Cited by 105
Role of Tight Glycemic Control during Acute Coronary Syndrome on CV Outcome in Type 2 Diabetes
Sasso, F. C., Rinaldi, L., Lascar, N., Marrone, A., Pafundi, P. C., Adinolfi, L. E., & Marfella, R. (2018) · Journal of Diabetes Research · doi:10.1155/2018/3106056 · Cited by 104
Self-citationCanagliflozin Improves Erythropoiesis in Diabetes Patients with Anemia of Chronic Kidney Disease
Maruyama, T., Takashima, H., Oguma, H., Nakamura, Y., Ohno, M., Utsunomiya, K., Furukawa, T., Tei, R., & Abe, M. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0212 · Cited by 103
Empagliflozin Protects against Diet-Induced NLRP-3 Inflammasome Activation and Lipid Accumulation
Benetti, E., Mastrocola, R., Vitarelli, G., Cutrìn, J. C., Nigro, D., Chiazza, F., Mayoux, E., Collino, M., & Fantozzi, R. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.235069 · Cited by 102
Metabolic and neuroprotective effects of dapagliflozin and liraglutide in diabetic mice
Millar, P., Pathak, N., Parthsarathy, V., Bjourson, A. J., O’Kane, M., Pathak, V., Moffett, R. C., Flatt, P. R., & Gault, V. A. (2017) · Journal of Endocrinology · doi:10.1530/joe-17-0263 · Cited by 102
Autonomic dysfunction is associated with brief episodes of atrial fibrillation in type 2 diabetes
Rizzo, M. R., Sasso, F. C., Marfella, R., Siniscalchi, M., Paolisso, P., Carbonara, O., Capoluongo, M. C., Lascar, N., Pace, C., Sardu, C., et al. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.09.002 · Cited by 100
Self-citationThe anti-diabetic drug dapagliflozin induces vasodilation via activation of PKG and Kv channels
Li, H., Shin, S. E., Seo, M. S., An, J. R., Choi, I., Jung, W., Firth, A. L., Lee, D.-S., Yim, M., Choi, G., et al. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.01.032 · Cited by 99
Pelletier, R., Ng, K., Alkabbani, W., Labib, Y., Mourad, N., & Gamble, J. (2021) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098621989134 · Cited by 99
Sjöström, C. D., Johansson, P., Ptaszynska, A., List, J., & Johnsson, E. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164115585298 · Cited by 97
Masarone, M., Rosato, V., Aglitti, A., Bucci, T., Caruso, R., Salvatore, T., Sasso, F. C., Tripodi, M. F., & Persico, M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0178473 · Cited by 97
Self-citationHeise, T., Jordan, J., Wanner, C., Heer, M. A., Macha, S., Mattheus, M., Lund, S. S., Woerle, H. J., & Broedl, U. C. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.09.001 · Cited by 96
Maeda, S., Matsui, T., Takeuchi, M., & Yamagishi, S. (2013) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2407 · Cited by 95
The Effects of Dapagliflozin on Systemic and Renal Vascular Function Display an Epigenetic Signature
Solini, A., Seghieri, M., Giannini, L., Biancalana, E., Parolini, F., Rossi, C., Dardano, A., Taddei, S., Ghiadoni, L., & Bruno, R. M. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00706 · Cited by 95
Lombardi, R., Airaghi, L., Targher, G., Serviddio, G., Maffi, G., Mantovani, A., Maffeis, C., Colecchia, A., Villani, R., Rinaldi, L., et al. (2019) · Liver International · doi:10.1111/liv.14274 · Cited by 91
Self-citationIL-6 receptor blockade ameliorates diabetic nephropathy via inhibiting inflammasome in mice
Wu, R., Liu, X., Yin, J., Wu, H., Cai, X., Wang, N., Qian, Y., & Wang, F. (2018) · Metabolism · doi:10.1016/j.metabol.2018.01.002 · Cited by 90
Complicated urinary tract infections with diabetes mellitus
Kamei, J., & Yamamoto, S. (2021) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2021.05.012 · Cited by 90
Vallon, V., Schroth, J., Satriano, J. A., Blantz, R. C., Thomson, S. C., & Rieg, T. (2009) · Nephron Physiology · doi:10.1159/000208211 · Cited by 89
Min, S. H., Yoon, J., Hahn, S., & Cho, Y. M. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2818 · Cited by 88
Sugiyama, S., Jinnouchi, H., Kurinami, N., Hieshima, K., Yoshida, A., Jinnouchi, K., Nishimura, H., Suzuki, T., MIYAMOTO, F., Kajiwara, K., et al. (2018) · Internal Medicine · doi:10.2169/internalmedicine.0701-17 · Cited by 88
Fitchett, D., Inzucchi, S. E., Zinman, B., Wanner, C., Schumacher, M., Schmoor, C., Ohneberg, K., Ofstad, A. P., Salsali, A., George, J. T., et al. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13615 · Cited by 85
Solute transport and oxygen consumption along the nephrons: effects of Na+transport inhibitors
Layton, A. T., Laghmani, K., Vallon, V., & Edwards, A. (2016) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00294.2016 · Cited by 83
Proteomics analysis reveals diabetic kidney as a ketogenic organ in type 2 diabetes
Zhang, D., Yang, H., Kong, X., Wang, K., Mao, X., Yan, X., Wang, Y., Liu, S., Zhang, X., Li, J., et al. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00308.2010 · Cited by 81
Cardiovascular and Renal Benefits of SGLT2 Inhibitors: A Narrative Review
Rabizadeh, S., Nakhjavani, M., & Esteghamati, A. (2019) · Intern J Endocrinol Metab · doi:10.5812/ijem.84353 · Cited by 81
Dimitrakoudis, D., Vranić, M., & Klip, A. (1992) · Journal of the American Society of Nephrology · doi:10.1681/asn.v351078 · Cited by 79
Thiele, K., Rau, M., Hartmann, N. K., Möllmann, J., Jankowski, J., Böhm, M., Keszei, A. P., Marx, N., & Lehrke, M. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14517 · Cited by 77
Symeonidis, A. S., Kouraklis‐Symeonidis, A., Psiroyiannis, A., Leotsinidis, M., Kyriazopoulou, V. E., Vassilakos, P. J., Vagenakis, A. G., & Zoumbos, N. C. (2005) · Annals of Hematology · doi:10.1007/s00277-005-1102-9 · Cited by 76
Sasso, F. C., Salvatore, T., Tranchino, G., Cozzolino, D., Caruso, A. A., Persico, M., Gentile, S., Torella, D., & Torella, R. (1999) · Metabolism · doi:10.1016/s0026-0495(99)90141-5 · Cited by 76
Self-citationSystematic review and meta-analysis: SGLT2 inhibitors, blood pressure and cardiovascular outcomes
Benham, J. L., Booth, J. E., Sigal, R. J., Daskalopoulou, S. S., Leung, A. A. C., & Rabi, D. M. (2021) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2021.100725 · Cited by 76
Yasui, A., Lee, G., Hirase, T., Kaneko, T., Kaspers, S., von Eynatten, M., & Okamura, T. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0385-5 · Cited by 75
Sasso, F. C., Nicola, L. D., Carbonara, O., Nasti, R., Minutolo, R., Salvatore, T., Conte, G., Torella, R., & for the NID-2 (Nephropathy in Diabetes-Type 2) Study Group (2006) · Diabetes Care · doi:10.2337/diacare.29.03.06.dc05-1776 · Cited by 75
Self-citationCohen, N. D., Gutman, S., Briganti, E. M., & Taylor, A. J. (2019) · Internal Medicine Journal · doi:10.1111/imj.14260 · Cited by 74
Huang, F., Zhao, Y., Wang, Q., Hillebrands, J., van den Born, J., Ji, L., An, T., & Qin, G. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00441 · Cited by 74
Renal Effects of Sodium-Glucose Co-Transporter Inhibitors
Thomson, S. C., & Vallon, V. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.10.027 · Cited by 74
Cardiovascular Benefits from Gliflozins: Effects on Endothelial Function
Salvatore, T., Caturano, A., Galiero, R., Martino, A. D., Albanese, G., Vetrano, E., Sardu, C., Marfella, R., Rinaldi, L., & Sasso, F. C. (2021) · Biomedicines · doi:10.3390/biomedicines9101356 · Cited by 74
Self-citationCaturano, A., Galiero, R., Pafundi, P. C., Cesaro, A., Vetrano, E., Palmiero, G., Rinaldi, L., Salvatore, T., Marfella, R., Sardu, C., et al. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108959 · Cited by 73
Self-citationNa+channel function, regulation, structure, trafficking and sequestration
Chen‐Izu, Y., Shaw, R. M., Pitt, G. S., Yarov-Yarovoy, V. M., Sack, J. T., Abriel, H., Aldrich, R. W., Belardinelli, L., Cannell, M. B., Catterall, W. A., et al. (2015) · The Journal of Physiology · doi:10.1113/jphysiol.2014.281428 · Cited by 72
Yang, Y., Chen, S., Pan, H., Zou, Y., Wang, B., Wang, G., & Zhu, H. (2017) · Medicine · doi:10.1097/md.0000000000006944 · Cited by 72
Tight Glycemic Control May Increase Regenerative Potential of Myocardium during Acute Infarction
Marfella, R., Sasso, F. C., Cacciapuoti, F., Portoghese, M., Rizzo, M. R., Siniscalchi, M., Carbonara, O., Ferraraccio, F., Torella, M., Petrella, A., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2037 · Cited by 71
Self-citationSGLT-2 inhibitors: pharmacokinetics characteristics and effects on lipids
Filippas-Ntekouan, S., Tsimihodimos, V., Filippatos, T. D., Dimitriou, T., & Elisaf, M. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1541348 · Cited by 71
Effect of renal tubule-specific knockdown of the Na+/H+exchanger NHE3 in Akita diabetic mice
Onishi, A., Fu, Y., Darshi, M., Crespo-Masip, M., Huang, W., Song, P., Patel, R., Kim, Y. C., Nespoux, J., Freeman, B., et al. (2019) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00497.2018 · Cited by 71
Cardioprotection by SGLT2 Inhibitors—Does It All Come Down to Na+?
Trum, M., Riechel, J., & Wagner, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22157976 · Cited by 71
Sasso, F. C., Chiodini, P., Carbonara, O., Nicola, L. D., Conte, G., Salvatore, T., Nasti, R., Marfella, R., Gallo, C., Signoriello, S., et al. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfr644 · Cited by 69
Self-citationGuo, M., Ding, J., Li, J., Wang, J., Zhang, T. D., Liu, C., Huang, W. G., Long, Y., Gao, C., & Xu, Y. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13295 · Cited by 69
Song, P., Huang, W., Ōnishi, A., Patel, R., Kim, Y. C., van Ginkel, C., Fu, Y., Freeman, B., Koepsell, H., Thomson, S. C., et al. (2019) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00120.2019 · Cited by 69
Effect of Dapagliflozin Treatment on Fluid and Electrolyte Balance in Diabetic Rats
Chen, L., LaRocque, L. M., Efe, O., Wang, J., Sands, J. M., & Klein, J. D. (2016) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2016.08.015 · Cited by 68
Leptin’s regulation of obesity-induced cardiac extracellular matrix remodeling
Zibadi, S., Cordova-Marks, F. M., Slack, E. H., WATSON, R. R., & Larson, D. F. (2011) · Cardiovascular Toxicology · doi:10.1007/s12012-011-9124-0 · Cited by 67
Wang, C., Chen, C., Lin, M.-H., Su, H., Ho, M.-Y., Yeh, J., Tsai, M., Hsieh, C., & Wen, M. (2020) · Biology · doi:10.3390/biology9110369 · Cited by 67
Elkazzaz, S. K., Khodeer, D. M., Fayoumi, H. M. E., & Moustafa, Y. M. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119018 · Cited by 67
Minutolo, R., Sasso, F. C., Chiodini, P., Cianciaruso, B., Carbonara, O., Zamboli, P., Tirino, G., Pota, A., Torella, R., Conte, G., et al. (2006) · Journal of Hypertension · doi:10.1097/01.hjh.0000239303.93872.31 · Cited by 65
Self-citationLi, D., Shi, W., Wang, T., & Tang, H. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13294 · Cited by 65
Bray, J. J. H., Foster-Davies, H., & Stephens, J. W. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108368 · Cited by 64
Hypoxia-inducible factor activation in diabetic kidney disease
Persson, P., & Palm, F. (2017) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000341 · Cited by 63
Salvatore, T., Galiero, R., Caturano, A., Vetrano, E., Rinaldi, L., Coviello, F., Di Martino, A., Albanese, G., Colantuoni, S., Medicamento, G., et al. (2022) · Biomolecules · doi:10.3390/biom12020176 · Cited by 62
Self-citationIncreased NHE3 abundance and transport activity in renal proximal tubule of rats with heart failure
Inoue, B. H., dos SANTOS, L., Pessoa, T. D., Antônio, E. L., Pacheco, B. P. M., Savignano, F. A., Carraro‐Lacroix, L. R., Tucci, P. J. F., Malnic, G., & Girardi, A. C. C. (2011) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00127.2011 · Cited by 62
Telemedicine for screening diabetic retinopathy: The NO BLIND Italian multicenter study
Sasso, F. C., Pafundi, P. C., Gelso, A., Bono, V., Costagliola, C., Marfella, R., Sardu, C., Rinaldi, L., Galiero, R., Acierno, C., et al. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3113 · Cited by 62
Self-citationÇalapkulu, M., Cander, S., Gül, Ö. Ö., & Ersoy, C. (2019) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2019.01.016 · Cited by 62
Mulder, S., Hammarstedt, A., Nagaraj, S. B., Nair, V., Ju, W., Hedberg, J., Greasley, P. J., Eriksson, J. W., Oscarsson, J., & Heerspink, H. J. L. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14018 · Cited by 62
Tanaka, A., Shimabukuro, M., Machii, N., Teragawa, H., Okada, Y., Shima, K. R., Takamura, T., Taguchi, I., Hisauchi, I., Toyoda, S., et al. (2019) · Diabetes Care · doi:10.2337/dc19-1177 · Cited by 60
Liu, Y., Xu, J., Wu, M., Xu, B., & Kang, L. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01430-y · Cited by 56
Mirabelli, M., CHIEFARI, E. D., Caroleo, P., Vero, R., Brunetti, F. S., Corigliano, D. M., Arcidiacono, B., FOTI, D. P., Puccio, L., & Brunetti, A. (2019) · Journal of Diabetes Research · doi:10.1155/2019/3971060 · Cited by 55
Avogaro, A., Fadini, G. P., & Prato, S. D. (2019) · Diabetes Care · doi:10.2337/dc19-1410 · Cited by 55
Katakami, N., Mita, T., Yoshii, H., Shiraiwa, T., Yasuda, T., Okada, Y., Torimoto, K., Umayahara, Y., Kaneto, H., Osonoi, T., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01206-1 · Cited by 55
Yang, Y., Zhao, C., Ye, Y., Yu, M., & Qu, X. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00190 · Cited by 53
Late sodium current associated cardiac electrophysiological and mechanical dysfunction
Yu, S., Li, G., Huang, C. L.-H., Lei, M., & Wu, L. (2017) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-017-2079-7 · Cited by 52
Rahman, A., Hitomi, H., & Nishiyama, A. (2017) · Hypertension Research · doi:10.1038/hr.2016.193 · Cited by 49
Merovci, A., Abdul‐Ghani, M. A., Mari, A., Solis‐Herrera, C., Xiong, J., Daniele, G., Tripathy, D., & DeFronzo, R. A. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2597 · Cited by 48
Scheen, A. J., & Delanaye, P. (2017) · Diabetes & Metabolism · doi:10.1016/j.diabet.2016.12.010 · Cited by 47
Nephroprotection by SGLT2 Inhibition: Back to the Future?
Nicola, L. D., Gabbai, F. B., Garofalo, C., Conte, G., & Minutolo, R. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072243 · Cited by 47
Sayour, A. A., Oláh, A., Ruppert, M., Barta, B. A., Horvath, E. M., Benke, K., Pólos, M., Hartyánszky, I. L., Merkely, B. P., & Radovits, T. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01141-1 · Cited by 47
Mini Review: Reappraisal of Uric Acid in Chronic Kidney Disease
Goldberg, A., García‐Arroyo, F. E., Sasai, F., Rodríguez‐Iturbe, B., Sánchez‐Lozada, L. G., Lanaspa, M. A., & Johnson, R. J. (2021) · American Journal of Nephrology · doi:10.1159/000519491 · Cited by 47
Wang, J., Chen, Y., Xu, W., Lu, N., Cao, J., & Yu, S. (2019) · PLOS ONE · doi:10.1371/journal.pone.0215362 · Cited by 45
Lü, J., Tang, L., Meng, H., Zhao, J., & Liang, Y. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3169 · Cited by 45
Vlotides, G., & Mertens, P. R. (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfu299 · Cited by 44
SGLT2 inhibitors may offer benefit beyond diabetes
Kang, A., & Jardine, M. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00391-2 · Cited by 43
Zhao, X., Chen, X., Zhang, Y., George, J., Cobbs, A., Wang, G., Li, L., & Emmett, N. L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20143406 · Cited by 42
García-Pastor, C., Martínez, S. B., Moreno‐Manzano, V., Fernández‐Martínez, A. B., & Lucio-Cazaña, F. J. (2019) · Scientific Reports · doi:10.1038/s41598-019-52310-6 · Cited by 42
Sodium glucose cotransporter 2 inhibitors: mechanisms of action in heart failure
Dutka, M., Bobiński, R., Ulman-Włodarz, I., Hajduga, M. B., Bujok, J., Pająk, C., & Ćwiertnia, M. (2020) · Heart Failure Reviews · doi:10.1007/s10741-020-10041-1 · Cited by 42
Wang, H., Yang, J., Chen, X., Qiu, F., & Li, J. (2019) · Clinical Therapeutics · doi:10.1016/j.clinthera.2019.01.001 · Cited by 36
Giugliano, D., Nicola, L. D., Maiorino, M. I., Bellastella, G., Garofalo, C., Chiodini, P., Ceriello, A., & Esposito, K. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01010-x · Cited by 35
Kidney hemodynamics after ketone body and amino acid infusion in normal and IDDM subjects
Nosadini, R., Trevisan, R., Fioretto, P., Semplicini, A., Samà, B., Velussi, M., Luigi Da Campo, G., Avogaro, A., Vizzaccaro, A., Donadon, V., et al. (1989) · Diabetes · doi:10.2337/diab.38.1.75 · Cited by 34
Satou, R., Cypress, M. W., Woods, T. C., Katsurada, A., Dugas, C. M., Fonseca, V. A., & Navar, L. G. (2019) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00402.2019 · Cited by 34
“The pharmacological profile of SGLT2 inhibitors: Focus on mechanistic aspects and pharmacogenomics”
Kaur, P., Behera, B. S., Singh, S., & Munshi, A. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174169 · Cited by 34
Hare, G. M. T., Zhang, Y., Chin, K., Thai, K., Jacobs, E., Cazorla‐Bak, M. P., Nghiem, L., Wilson, D. F., Vinogradov, S. A., Connelly, K. A., et al. (2021) · Physiological Reports · doi:10.14814/phy2.14890 · Cited by 33
Uptake of ketone bodies by dog kidney in vivo
Little, & Spitzer, J. J. (1971) · American Journal of Physiology-Legacy Content · doi:10.1152/ajplegacy.1971.221.3.679 · Cited by 31
Irace, C., Cutruzzolà, A., Parise, M., Fiorentino, R., Frazzetto, M., Gnasso, C., Casciaro, F., & Gnasso, A. (2019) · Diabetes and Vascular Disease Research · doi:10.1177/1479164119883540 · Cited by 30
Hu, S., Lin, C., Cai, X., Zhu, X., Lv, F., Nie, L., & Ji, L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.814074 · Cited by 29
Inagaki, N., Goda, M., Yokota, S., Maruyama, N., & Iijima, H. (2015) · Advances in Therapy · doi:10.1007/s12325-015-0255-8 · Cited by 27
Hao, Z., Huang, X. D., Shao, H., & Tian, F. (2018) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s186347 · Cited by 27
Potential Impact on Lipoprotein Subfractions in Type 2 Diabetes
Kamijo, Y., Ishii, H., Yamamoto, T., Kobayashi, K., Asano, H., Miake, S., Kanda, E., Urata, H., & Yoshida, M. (2019) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/1179551419866811 · Cited by 26
Galiero, R., Ricciardi, D., Pafundi, P. C., Todisco, V., Tedeschi, G., Cirillo, G., & Sasso, F. C. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108856 · Cited by 26
Self-citationLiao, H., Wu, Y., Sue, Y., Lee, M., & Ovbiagele, B. I. (2018) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.50 · Cited by 25
Hattori, Y. (2021) · Heart Failure Reviews · doi:10.1007/s10741-020-10065-7 · Cited by 25
Lipid effects of sodium-glucose cotransporter 2 inhibitors
Lazarte, J., Kanagalingam, T., & Hegele, R. A. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000751 · Cited by 25
Vaduganathan, M., Inzucchi, S. E., Sattar, N. A., FITCHETT, D. H., Ofstad, A. P., Brueckmann, M., George, J. T., Verma, S., Mattheus, M., Wanner, C., et al. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14535 · Cited by 25
Kidney in Diabetes: from Organ Damage Target to Therapeutic Target
Salvatore, T., Carbonara, O., Cozzolino, D., Torella, R., Nasti, R., Lascar, N., & Sasso, F. C. (2011) · Current Drug Metabolism · doi:10.2174/138920011796504509 · Cited by 24
Self-citationPatoulias, D., Stavropoulos, K., Imprialos, K. P., Katsimardou, A., Kalogirou, M., Koutsampasopoulos, K., Zografou, I., Papadopoulos, C. E., Karagiannis, A. I., & Doumas, M. N. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107927 · Cited by 24
Chen, M.-B., Wang, H., Cui, W.-Y., Xu, H.-L., & Zheng, Q.-H. (2021) · Medicine · doi:10.1097/md.0000000000024593 · Cited by 23
Yanai, H., & Katsuyayama, H. (2016) · Journal of Clinical Medicine Research · doi:10.14740/jocmr2857w · Cited by 21
Cherukuri, L., Smith, M. S., & Tayek, J. A. (2018) · doi:10.31038/edmj.2018232 · Cited by 21
Nabrdalik-Leśniak, D., Nabrdalik, K., Sedlaczek, K., Główczyński, P., Kwiendacz, H., Sawczyn, T., Hajzler, W., Drożdż, K., Hendel, M., Irlik, K., et al. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/5593589 · Cited by 21
Jurczak, M. J., Saini, S., Ioja, S., Costa, D. K., Udeh, N., Zhao, X., Whaley, J. M., & Kibbey, R. G. (2018) · Islets · doi:10.1080/19382014.2018.1503027 · Cited by 19
Loss of CASK Accelerates Heart Failure Development
Mustroph, J., Sag, C. M., Bähr, F., Schmidtmann, A.-L., Gupta, S. N., Dietz, A., Islam, M. M. T., Lücht, C., Beuthner, B. E., Pabel, S., et al. (2021) · Circulation Research · doi:10.1161/circresaha.120.318170 · Cited by 19
Tamura, K., Wakui, H., Azushima, K., Uneda, K., & Umemura, S. (2016) · Hypertension Research · doi:10.1038/hr.2016.1 · Cited by 17
Barraclough, J., Patel, S., Yu, J., Neal, B. C., & Arnott, C. G. (2021) · Cells · doi:10.3390/cells10102699 · Cited by 14
Does SGLT2 Inhibition Affect Sympathetic Nerve Activity in Type 2 Diabetes?
Dimova, R. B., & Tankova, T. I. (2020) · Hormone and Metabolic Research · doi:10.1055/a-1298-4205 · Cited by 12
Bailey, C. J., Prato, S. D., Wei, C., Reyner, D., & Saraiva, G. L. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13841 · Cited by 11
Li, D., Zou, H., Yin, P., Li, W., He, J., Wang, S., Huang, L., Shao, S., Chen, Y., Yang, Y., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14217 · Cited by 11
Wysham, C., Lefèbvre, P., Pilon, D., Lafeuille, M., Émond, B., Kamstra, R. L., Pfeifer, M., Duh, M. S., & Ingham, M. (2018) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2018.10.016 · Cited by 6
Cited by
Guo, W., Song, Y., Sun, Y., Du, H., Cai, Y., You, Q., Fu, H., & Shao, L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1071465 · Cited by 335
Salvatore, T., Galiero, R., Caturano, A., Vetrano, E., Loffredo, G., Rinaldi, L., Catalini, C., Gjeloshi, K., Albanese, G., Di Martino, A., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10092274 · Cited by 98
Self-citation
Metadata
- Authors
- Salvatore, T., Galiero, R., Caturano, A., Rinaldi, L., Di Martino, A., Albanese, G., Di Salvo, J., Epifani, R., Marfella, R., Docimo, G., Lettieri, M., Sardu, C., & Sasso, F. C.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-03-26
- Volume
- 23
- Issue
- 7
- Pages
- 3651
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W4220742762
- Cited by
- 256
- References
- 346
- FWCI
- 31.47
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.